Robert Roth

机构：AstraZeneca (Singapore), AstraZeneca (Switzerland), AstraZeneca (Germany) · ORCID：0000-0002-7084-6947

发表论文 39 篇 · 总被引 768 次 · h-index 15

代表论文

• MALT1 Auto-Proteolysis Is Essential for NF-κB-Dependent Gene Transcription in Activated Lymphocytes (2014 · PLoS ONE · 被引 75)
• Systematic Evaluation of CRISPRa and CRISPRi Modalities Enables Development of a Multiplexed, Orthogonal Gene Activation and Repression System (2019 · ACS Synthetic Biology · 被引 57)
• Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins (2022 · Metabolic Engineering · 被引 46)
• Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design (2015 · PLoS ONE · 被引 38)
• Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay (2021 · Clinical & Translational Immunology · 被引 37)
• Structure and biophysical characterization of the human full-length neurturin–GFRa2 complex: A role for heparan sulfate in signaling (2018 · Journal of Biological Chemistry · 被引 36)